Table 3.
Resistance mutations, viral subtypes, and ART.
| ART | Mutations | Treatment status | Subtypes | Total n (%) | ||
|---|---|---|---|---|---|---|
| ART (n) | Naïve (n) | 02_AG (n) | Non-02_AG (n) | |||
| NRTI | M184V | 9 | 3 | 6 | 5 | 11(58) |
| T69D | 1 | 1 | 2 | — | 2(11) | |
| K65R | — | 1 | 1 | — | 1(5) | |
| Y115F | — | 1 | 1 | — | 1(5) | |
| K219E/Q | 4 | — | 2 | 2 | 4(21) | |
| D67N | 2 | — | — | 2 | 2(11) | |
| K70R | 3 | — | 1 | 2 | 3(16) | |
| T215F | 2 | 1 | 2 | 1 | 3(16) | |
| NNRTI | Y181C | 2 | 1 | 3 | — | 3(12) |
| V106M/A | 3 | — | 1 | 2 | 5(20) | |
| V108I | 1 | 1 | 2 | — | 2(8) | |
| K103N | 3 | 4 | 4 | 3 | 7(28) | |
| P225H | 1 | 1 | 2 | — | 2(8) | |
| L100I | 1 | 1 | 1 | 1 | 2(8) | |
| K101E | — | 1 | — | 1 | 1(4) | |
| Y188L | 1 | 1 | 1 | 1 | 2(8) | |
| PI | V82L | — | 1 | — | 1 | 1(4) |
NRTI: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors; NNRTI: Non- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor; PI: Protease Inhibitor; n: sample size; ART: antiretroviral therapy; 02_AG: HIV-1 CRF02_AG.